Drugs / ADX-324
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05691361 | Dec 2022 → Dec 2027 expected | hereditary angioedema | ADARx Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07428499 | Apr 2026 → Jun 2030 expected | hereditary angioedema type 1, hereditary angioedema type 2 | ADARx Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT06960213 | Aug 2025 → Jun 2027 expected | hereditary angioedema type 1, hereditary angioedema type 2 | ADARx Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
Press releases naming this drug 6 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADX-324 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05691361 ↗ |
| Modality | Small interfering RNA (siRNA) | “siRNA duplex oligonucleotide” NCT05691361 ↗ |